Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Dermatological Medicine
Volume 2017, Article ID 2386234, 3 pages
Case Report

Repigmentation of Tenacious Vitiligo on Apremilast

1University of Toledo College of Medicine and Life Sciences, 3000 Arlington Avenue, Toledo, OH 43614, USA
2Department of Dermatology, University of Toledo Medical Center, 3000 Arlington Avenue, Toledo, OH 43614, USA

Correspondence should be addressed to Sara B. Huff; ude.odelotu@eornom.aras

Received 26 July 2017; Accepted 8 October 2017; Published 6 November 2017

Academic Editor: Kowichi Jimbow

Copyright © 2017 Sara B. Huff and Lorie D. Gottwald. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Vitiligo is a common pigment disorder characterized by acquired loss of function or absence of melanocytes, leading to distinct areas of depigmentation. Physical exam reveals sharply demarcated, depigmented macules or patches on otherwise normal skin. Vitiligo can present at any age, in any skin color. There is no specific serologic marker for diagnosis, but patients often have other autoimmune problems. Treatment options are limited and are difficult given the fact that the pathogenesis of the disease is not well elucidated. We present the case of a 52-year-old woman with vitiligo for over 2 decades. The patient’s medical history reveals a lack of response to many different approaches. This case highlights the ability of apremilast, an FDA-approved drug for the treatment of psoriasis and psoriatic arthritis, to achieve repigmentation in a case a vitiligo that has been extremely recalcitrant.